To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Febico Biomedical Corp.
- Target Recruit Count
- 120
- Registration Number
- NCT06478719
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath